Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963902 | 0.85 | TSPO (0.49) | NR3C1CRHBPCRHR2KMT2ATSPO | |
| SCHEMBL1612858 | 0.82 | KMT2A (0.53) | NR3C1ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL12950801 | 0.78 | CRHBP (0.51) | NR3C1ALDH1A1KDM4EHPGDCRHBP | |
| SCHEMBL30910355 | 0.78 | PLA2G2A (0.49) | NR3C1ALDH1A1KDM4EHPGDCRHBP | |
| SCHEMBL28316742 | 0.77 | LMNA (0.47) | NR3C1ALDH1A1KDM4EHPGDCRHBP | |
| SCHEMBL28499366 | 0.75 | CNR1 (0.43) | NR3C1ALDH1A1KDM4EHPGDCRHBP | |
| SCHEMBL21231985 | 0.73 | MAPK14 (0.43) | NR3C1ALDH1A1KDM4EHPGDCRHBP | |
| SCHEMBL26105961 | 0.72 | SLC16A3 (0.52) | HPGDCRHBPCRHR2LMNA | |
| SCHEMBL30394561 | 0.72 | SLC16A3 (0.52) | HPGDCRHBPCRHR2LMNA | |
| SCHEMBL21231986 | 0.72 | KDM4E (0.42) | NR3C1ALDH1A1KDM4EHPGDCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| CN-114007695-A | As AM2Heterocyclic spiro-compounds as receptor inhibitors | 谢菲尔德大学 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020099885-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | NR3C1 234/4885ALDH1A1 2923/4885KDM4E 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.